The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
This second webinar in our SDOH series will feature KOLs emphasizing applied learnings in the SDOH and population health fields. The session will address collaborative patient engagement: how styles of communication, analytics, telemedicine and PHM are tackling social risks and engaging patients in the pandemic/infodemic era.
Manufacturing has been widely recognized as a bottleneck to bring advanced cell and gene therapies to the patients and families in need. The question is, should organizations stay the course internally, or look externally for their manufacturing needs?
Join MassBio and Precision for a one-of-a-kind panel discussion with a unique group of experts in cell and gene therapy studies. These pioneers have been involved in multiple programs that led to FDA-approved cell and gene therapies. They will share lessons learned from experience, giving you actionable insights on every stage of a trial—from the lab, to studies, to logistics and biomanufacturing.
Moderated by Precision’s Ross Maclean, join our distinguished panel of experts as they provide key insights on why social determinants of health (SDOH) are critical factors to inform today’s treatment planning, care delivery, health policy, health outcomes and value.
In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers.
Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Adding to the discussion, Precision will explore how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.
As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. However, so far, gene therapies have targeted smaller indications and the prospect of treating much higher numbers at the price benchmarks already set may prove challenging for payers and health systems to provide access.
Join Precision and Akara Group for a special online discussion of best practices for pre-launch commercialization activities. Featuring Precision’s Brett DiNatale, learn about the latest advances in data, analytics, and technology, and understand how these latest advances can be used to improve decisions that impact GTN.